MD

Medtronic plc

MDTHealthcareNASDAQ

Medical Devices

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$36.36B
+8.4% YoY
Net Income
$4.80B
+3.0% YoY
EBITDA
$9.81B
+6.4% YoY
Free Cash Flow
$5.41B

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 31 MACD Negative CrossoverHistogram -0.3283, negative momentum
Aug 29 MACD Negative CrossoverHistogram -0.3283, negative momentum
About Medtronic plc

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. At a $118.18B market cap, Medtronic plc ranks as a large-cap company within healthcare. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio.

Where MDT stands vs its 150-day and 200-day moving averages

As of the August 31, 2026 close, MDT finished 6.19% above its 150-day moving average ($85.91) and 2.85% above its 200-day moving average ($88.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is MDT overbought or oversold?

At the August 31, 2026 close, MDT's RSI(14) was 55.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$118.18B
P/E (TTM)22.76
Fwd P/E14.44
EPS$4.06
Beta0.57
52W Change+2.0%
Dividend Yield3.06%
ROE10.7%
Analysis

The company holds $8.82B in cash, though total debt stands at $28.15B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $5.41B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 10.7%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $31.23B to $36.36B.

With a beta below 0.7, Medtronic plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Medtronic plc and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms